Wegovy explained in plain English

Is Wegovy actually licensed for weight loss, or is this the diabetes drug I keep hearing about?

This is the question our prescribers hear most weeks, and the confusion is understandable. Semaglutide exists under two brand names in the UK: Ozempic for type 2 diabetes, and Wegovy for weight management. They share the same active molecule but carry different licences, different doses and different regulatory histories. Using Ozempic for weight loss is off-label; Wegovy is the weight-management product, approved specifically for that purpose by the MHRA.

The full Wegovy overview on this site covers the licence in detail, but the short version is this: Wegovy is approved for adults with a BMI of 30 or above, or 27 to 29.9 with at least one weight-related condition such as high blood pressure or prediabetes. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. A BMI number alone does not guarantee a prescription, the prescriber looks at your whole health profile, including anything that might make the medicine unsuitable.

One thing worth knowing: Wegovy carries a Black Triangle (▼) designation from the MHRA, meaning it is subject to additional monitoring. That is normal for newer medicines and does not mean it is experimental. The NHS medicines page for semaglutide on NHS.uk explains this clearly and lists the conditions where it should be avoided or used with care.

What the evidence actually says about how much weight people lose

The headline trial is STEP 1, published in the New England Journal of Medicine: 68 weeks, semaglutide 2.4 mg versus placebo, 1,961 adults with obesity or overweight plus at least one weight-related condition. Average weight loss was around 15% of body weight on the active medicine, compared with roughly 2.4% on placebo. That is a meaningful difference, and it is the figure regulators based the UK licence on.

Since then, Novo Nordisk has received MHRA approval for a higher 7.2 mg dose, with trial data reporting around 20.7% average weight loss over 72 weeks. That narrows the gap with tirzepatide (Mounjaro), which showed around 20 to 21% at its highest dose in the SURMOUNT-1 trial. If you are deciding between the two, the treatment overview page sets out the practical comparison, but which medicine fits your situation is ultimately a clinical call.

One thing the trials consistently show is that results depend heavily on the lifestyle changes that accompany treatment. Wegovy is not a substitute for a lower-calorie diet and increased activity; it is designed to make those changes more achievable by reducing appetite. People who stopped treatment in the extension phases regained a significant proportion of the weight, which is why ongoing clinical support matters.

What the NHS covers and what private treatment involves

Wegovy is available on the NHS, but under NICE guidance (TA875) it must be prescribed within a specialist weight management service and used for a maximum of two years. Waiting lists for those services are commonly long in England, and eligibility criteria are strict. Wegovy's availability in England is covered separately if you want the detail on NHS access routes.

Private treatment through a regulated online pharmacy is the practical alternative for people who do not meet the current NHS criteria or do not want to wait. The route via a service like ours at nume involves a free clinical consultation reviewed by a GPhC-registered Independent Prescriber, identity and weight verification, and (once approved) same-day dispatch with free next-working-day delivery. Your order arrives via DPD in plain, unbranded packaging with a tracking notification on your phone; inside is the Wegovy pen itself, labelled with your prescription details.

For an honest look at what private Wegovy costs and what a quoted price should include, the Wegovy price guide works through the numbers. The short version: any legitimate private price should cover the prescription, clinical assessment and delivery, not just the pen.

Practical things worth knowing before you decide

Side effects are common, particularly in the first few weeks. The most frequently reported are gastrointestinal: nausea, diarrhoea, constipation and indigestion, usually at their worst after starting or following a dose increase, then settling. Serious side effects are less common but include pancreatitis. Seek urgent medical attention for severe stomach pain that radiates to the back, with or without vomiting. The things people wish they had known before starting Wegovy is a practical companion page on this.

Women using oral contraceptives should discuss the interaction with their prescriber before starting; absorption of hormonal pills can be affected during the early weeks of treatment. Wegovy is not recommended during pregnancy, breastfeeding or when trying to conceive, and it is not licensed for anyone under 18.

If you are unsure whether you are saying the name right, how to pronounce Wegovy in English is a short but genuinely useful page. And if your question is whether any of this applies to leg-related weight distribution, that page addresses it directly. Semaglutide works systemically, there is no targeted fat loss in a specific body part.

If you think Wegovy might be right for you, the first step is a clinical consultation. Start your free consultation at the treatment page, and a GPhC-registered prescriber will review your answers the same day.